جستارهای وابسته

منابع

1. ↑Fisar Z, Hroudová J, Raboch J (2010). "Inhibition of monoamine oxidase activity by antidepressants and mood stabilizers".Neuro Endocrinol Lett.31 (5): 645–56.PMID 21200377.
2. ↑Murphy DL, Karoum F, Pickar D, et al. (1998). "Differential trace amine alterations in individuals receiving acetylenic inhibitors of MAO-A (clorgyline) or MAO-B (selegiline and pargyline)".J. Neural Transm. Suppl. Journal of Neural Transmission. Supplement.52: 39–48.doi:10.1007/978-3-7091-6499-0_5.ISBN 978-3-211-83037-6.PMID 9564606.
3. ↑Edward Shorter, A historical dictionary of psychiatry. Oxford University Press, Inc 2005.شابک‎۰۱۹۵۱۷۶۶۸۵
4. ↑William M. Wardell and Louis Lasagna. Regulation Drug Development (Evaluative Studies 21) American Enterprise Institute (1975)شابک‎۰۸۴۴۷۳۱۶۷۶
5. ↑Council on DrugsNew Drugs and Developments in Therapeutics: Pargyline Hydrochloride (Eutonyl) JAMA. 1963;184(11):887. doi:10.1001/jama.1963.03700240079013.
6. ↑"Eutonyl and MAO inhibitors".Drug and Therapeutics Bulletin(به انگلیسی).1 (15): 59–60. 15 November 1963.doi:10.1136/dtb.1.15.59.ISSN 1755-5248.S2CID 220162992.Pargyline is promoted only for the treatment of hypertension, and not for depression.
7. ↑FDAEutonyl in the Drugs@FDA Database Accessed July 19, 2014
8. ↑Critical Reviews in Neurobiology. CRC Press. 1995. p. 43.